Zobrazeno 1 - 10 of 31 pro vyhledávání: '"Viral Load/drug effects"'
1
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure
Autor: Smith, David A., Fernandez-Antunez, Carlota, Magri, Andrea, Bowden, Rory, Chaturvedi, Nimisha, Fellay, Jacques, McLauchlan, John, Foster, Graham R., Irving, William L., Simmonds, Peter, Pedergnana, Vincent, Ramirez, Santseharay, Bukh, Jens, Barnes, Eleanor, Ansari, M. Azim, Ball, Jonathan, Brainard, Diana, Burgess, Gary, Cooke, Graham, Dillon, John, Gore, Charles, Guha, Neil, Halford, Rachel, Herath, Cham, Holmes, Chris, Howe, Anita, Hudson, Emma, Irving, William, Khakoo, Salim, Klenerman, Paul, Koletzki, Diana, Martin, Natasha, Massetto, Benedetta, Mbisa, Tamyo, McHutchison, John, McKeating, Jane, Miners, Alec, Murray, Andrea, Shaw, Peter, Spencer, Chris C. A., Targett-Adams, Paul, Thomson, Emma, Vickerman, Peter, Zitzmann, Nicole
Publikováno v: Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
STOP-HCV Consortium 2021, ' Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure ', Nature Communications, vol. 12, no. 1, 6105 . https://doi.org/10.1038/s41467-021-25649-6
Nature Communications, 2021, 12 (1), pp.6105. ⟨10.1038/s41467-021-25649-6⟩
Nature communications, vol. 12, no. 1, pp. 6105
Sofosbuvir is a common therapy in hepatitis C virus infection, which targets the NS5B polymerase. Here, Smith et al. analyze the association between whole genome HCV polymorphisms and sofosbuvir treatment failure and identify three common polymorphis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c9cf99c929fe18ff1ccaeb9a812b730
Zobrazit plný text záznamu
2
Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection
Autor: Lévy, Yves, Lelièvre, Jean-Daniel, Assoumou, Lambert, Aznar, Esther, Pulido, Federico, Tambussi, Giuseppe, Crespo, Manuel, Meybeck, Agnès, Molina, Jean-Michel, Delaugerre, Constance, Izopet, Jacques, Peytavin, Gilles, Cardon, Fanny, Diallo, Alpha, Lancar, Rémi, Béniguel, Lydie, Costagliola, Dominique
Publikováno v: Annals of Internal Medicine
Annals of Internal Medicine, American College of Physicians, 2020, 172 (5), pp.297-305. ⟨10.7326/M19-2133⟩
International audience; Background: Patients diagnosed with advanced HIV infection have a poor prognosis despite initiation of combined antiretroviral therapy (c-ART). Objective : To assess the benefit of adding maraviroc, an antiretroviral drug with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4325::373c10ef5347e3e82082d01fcacfc7e0
https://ut3-toulouseinp.hal.science/hal-03578146
Zobrazit plný text záznamu
3
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium
Autor: Bastian Neesgaard, Amanda Mocroft, Robert Zangerle, Ferdinand Wit, Fiona Lampe, Huldrych F Günthard, Coca Necsoi, Matthew Law, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Christian Pradier, Nikoloz Chkhartisvilli, Juliana Reyes-Uruena, Jörg Janne Vehreschild, Jan-Christian Wasmuth, Anders Sönnerborg, Christoph Stephan, Lauren Greenberg, Josep M Llibre, Alain Volny-Anne, Lars Peters, Annegret Pelchen-Matthews, Vani Vannappagari, Joel Gallant, Armin Rieger, Mike Youle, Dominique Braun, Stephane De Wit, Kathy Petoumenos, Vanni Borghi, Vincenzo Spagnuolo, Tengiz Tsertsvadze, Jens Lundgren, Lene Ryom, RESPOND study group
Publikováno v: Neesgaard, B, Mocroft, A, Zangerle, R, Wit, F, Lampe, F, Günthard, H F, Necsoi, C, Law, M, Mussini, C, Castagna, A, Monforte, A DA, Pradier, C, Chkhartisvilli, N, Reyes-Uruena, J, Vehreschild, J J, Wasmuth, J-C, Sönnerborg, A, Stephan, C, Greenberg, L, Llibre, J M, Volny-Anne, A, Peters, L, Pelchen-Matthews, A, Vannappagari, V, Gallant, J, Rieger, A, Youle, M, Braun, D, De Wit, S, Petoumenos, K, Borghi, V, Spagnuolo, V, Tsertsvadze, T, Lundgren, J, Ryom, L & RESPOND Study Group 2020, ' Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting : The RESPOND cohort consortium ', PLoS ONE, vol. 15, no. 12, e0243625 . https://doi.org/10.1371/journal.pone.0243625
PLoS ONE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PLoS ONE, Vol 15, Iss 12, p e0243625 (2020)
PLoS ONE, 15(12 December):e0243625. Public Library of Science
PloS one, 15 (12 December
Objectives To compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-lif
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b7e1131f1db9907055718899d452b1
Zobrazit plný text záznamu
4
Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial
Autor: Maja A. Sommerfelt, Gonzalo Tapia, Yunda Huang, Arnt-Ove Hovden, Mats Ökvist, Richard B. Pollard, Brittany Sanchez, Giuseppe Pantaleo, Lily Zhang, Jürgen K. Rockstroh, Monica Trondsen
Publikováno v: EBioMedicine, Vol 24, Iss C, Pp 195-204 (2017)
EBioMedicine, vol. 24, pp. 195-204
EBioMedicine
Background In a placebo-controlled trial of the peptide-based therapeutic HIV-1 p24Gag vaccine candidate Vacc-4x, participants on combination antiretroviral therapy (cART) received six immunizations over 18 weeks, followed by analytical treatment int
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b1a02fdb50036af690309124a9d69e
http://www.sciencedirect.com/science/article/pii/S2352396417303821
Zobrazit plný text záznamu
5
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients
Autor: Constance Delaugerre, Virginie Ferré, Anne Maillard, Vincent Calvez, Audrey Mirand, Anne-Geneviève Marcelin, Corinne Amiel, Julia Dina, Coralie Pallier, Hélène Le Guillou-Guillemette, Stéphanie Raymond, D. B. Fofana, Thomas Mourez, Hélène Jeulin, Samira Fafi-Kremer, Brigitte Montes, Pantxika Bellecave, Sophie Vallet, Thuy Van Nguyen, Diane Descamps, Catherine Roussel, Maxime Grude, Mary-Anne Trabaud, Charlotte Charpentier, Laurence Bocket, Philippe Flandre, Laura Le Guen, Anne Signori-Schmuck
Publikováno v: Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (5), pp.1368-1375. ⟨10.1093/jac/dkz021⟩
Journal of Antimicrobial Chemotherapy, 2019, 74 (5), pp.1368-1375. ⟨10.1093/jac/dkz021⟩
International audience; Objectives: To describe integrase strand transfer inhibitor (INSTI) resistance profiles and factors associated with resistance in antiretroviral-naive and -experienced patients failing an INSTI-based regimen in clinical practi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57b81aa0dcf188502b617cb295d23cbb
https://hal-normandie-univ.archives-ouvertes.fr/hal-02154049
Zobrazit plný text záznamu
6
Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
Autor: Alexandra Calmy, Charles Kouanfack, Sabrina Eymard-Duvernay, Mireille Mpoudi-Etame, Sylvie Boyer, Martine Peeters, Pierrette Omgba Bassega, Eric Delaporte, Sandrine Leroy
Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2019, 381 (9), pp.816-826. ⟨10.1056/NEJMoa1904340⟩
New England Journal of Medicine, 2019, 381 (9), pp.816-826. ⟨10.1056/NEJMoa1904340⟩
New England Journal of Medicine, Vol. 381, No 9 (2019) pp. 816-826
International audience; BACKGROUND: An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 20
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f97a7b4605ac78a60ffa320ad36429
https://hal.archives-ouvertes.fr/hal-02479607/file/nejmoa1904340.pdf
Zobrazit plný text záznamu
7
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Autor: Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Amanda E Clarke, Chien-Ching Hung, Jürgen K Rockstroh, Pierre-Marie Girard, Jörg Sievers, Choy Man, Alexander Currie, Mark Underwood, Allan R Tenorio, Keith Pappa, Brian Wynne, Anna Fettiplace, Martin Gartland, Michael Aboud, Kimberly Smith, Lidia Cassetti, Daniel David, Laura Figueras, Marcelo Losso, Gustavo Lopardo, Sergio Lupo, Norma Porteiro, Marisa Sánchez, Mark Bloch, David Cooper, Robert Finlayson, Anthony Kelleher, Kenneth Koh, David Lewis, James McMahon, Richard Moore, Norman Roth, Matthew Shields, Stephane De Wit, Eric Florence, Jean-Christophe Goffard, Remy Demeester, Patrick Lacor, Bernard Vandercam, Linos Vandekerckhove, Jonathan Angel, Jean-Guy Baril, Brian Conway, Alexandra De Pokomandy, Jason Szabo, Sharon Walmsley, Olivier Bouchaud, Christian Chidiac, Pierre Delobel, Cecile Goujard, Christine Katlama, Jean-Michel Molina, Gilles Pialoux, Patrick Philibert, Johannes Bogner, Stefan Esser, Ivanka Krznaric, Clara Lehmann, Christoph Spinner, Hans-Jurgen Stellbrink, Christoph Stephan, Albrecht Stoehr, Enrico Barchi, Pietro Caramello, Francesco Castelli, Anna Maria Cattelan, Antonella D'Arminio Monforte, Antonio Di Biagio, Giovanni Di Perri, Andrea Gori, Franco Maggiolo, Barbara Menzaghi, Guglielmo Migliorino, Cristina Mussini, Giovanni Penco, Massimo Puoti, Giuliano Rizzardini, Roberto Gulminetti, Adriano Lazzarin, Tiziano Quirino, Laura Sighinolfi, Pierluigi Viale, Gerardo Amaya Tapia, Jaime Andrade Villanueva, Enrique R Granados Reyes, Alma Perez Rios, Mario Santoscoy Gomez, Jan Den Hollander, Bart Rijnders, José A Hidalgo, Luis Hercilla Vasquez, Luis Illescas, Anita Olczak, Kamal Mansinho, Patricia Paula Correia Pacheco, Eugénio Teófilo, Jose Saraiva da Cunha, Rui Sarmento e Castro, Rosário Serrão, Manuela Arbune, Cristian Jianu, Anca Oprea, Liliana Preotescu, Liviu-Jany Prisacariu, Elena Belonosova, Olga Borodkina, Oxana Chernova, Natalia Gankina, Svetlana Kizhlo, Valeriy Kulagin, Nadezhda Kurina, Firaya Nagimova, Vadim Pokrovsky, Elena Ryamova, Evgeny Voronin, Alexey Yakovlev, Richard Kaplan, Sun Hee Lee, Shin-Woo Kim, Sang-Il Kim, Woo Joo Kim, Antonio Antela Lopez, Jose L Casado Osorio, Manuel A Castaño Carracedo, Ignacio De Los Santos Gil, Vicente Estrada Perez, Vicenç Falco Ferrer, Luis Force, Maria Jose Galinda Puerto, Miguel Garcia Deltoro, Josep M Gatell, Miguel A Goenaga Sanchez, Ana González Cordón, Hernando Knobel, Juan Carlos Lopez Bernaldo de Quiros, Juan E Losa Garcia, Mar Masia, Marta Montero-Alsonso, Antonio Ocampo Hermida, Juan Pasquau Liaño, Joaquin Portilla Sogorb, Federico Pulido Ortega, Antonio Rivera Roman, Jose Ramon Santos Fernandez, Rafael Torres Perea, Jesus Troya Garcia, Pompeyo Viciana Fernandez, Alexandra Calmy, Christoph Hauser, Jan Fehr, Shu-Hsing Cheng, Wen-Chien Ko, Hsi-Hsun Lin, Po-Liang Lu, Yu-Ting Tseng, Ning-Chi Wang, Wing-Wai Wong, Chia-Jui Yang, Roberto Arduino, Paul Benson, Mezgebe Berhe, Fritz Bredeek, Cynthia Brinson, Thomas Campbell, Gordon Crofoot, Douglas Cunningham, Edwin DeJesus, Robin Dretler, Joseph Eron, Kenneth Fife, Carl Fichtenbaum, Jason Flamm, Deborah Goldstein, Samir Gupta, Debbie Hagins, Margaret Hoffman-Terry, Dushyantha Jayaweera, Clifford Kinder, Daniel Klein, Cheryl McDonald, Anthony Mills, Ronald Nahass, Olayemi Osiyemi, Edgar Overton, David Parks, David Prelutsky, Moti Ramgopal, Shannon Schrader, Beverly Sha, Gary Simon, James Sims, Daniel Skiest, Jihad Slim, Karen Tashima, Blair Thedinger, Brian Gazzard, Julie Fox, Margaret Johnson, Stephen Kegg, Saye Khoo, Charles Mazhude, Chloe Orkin, Gabriel Schembri, Andrew Ustianowski
Publikováno v: The Lancet, 393(10167), 143-155. Elsevier Ltd.
Summary Background Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug regime
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad70b60db548619c808fac0879d6106
https://hdl.handle.net/11380/1221490
Zobrazit plný text záznamu
8
J Acquir Immune Defic Syndr
Autor: Daniel Gillor, Lars P. Ryder, Rodolphe Thiébaut, Luuk Gras, Santiago Moreno, Marie Helleberg, Peter Reiss, Michael S. Saag, Margaret T May, Jonathan A C Sterne, Ferdinand W. N. M. Wit, Janet Tate, Niels Obel, Frank de Wolf, Ronald B. Geskus, Colette Smith, José M. Miró, Jodie L. Guest, Dominique Costagliola, Suzanne M Ingle, Matthias Cavassini, Antonella dʼArminio Monforte, Heidi M. Crane, Marta Montero, Timothy R. Sterling, Leah Shepherd, Viviane D. Lima, Christoph Stephan, Adam Trickey, Armin Rieger, John Gill
Publikováno v: Journal of acquired immune deficiency syndromes, vol. 80, no. 3, pp. 292-300
Journal of Acquired Immune Deficiency Syndromes
Journal of Acquired Immune Deficiency Syndromes, Lippincott, Williams & Wilkins, 2019, 80 (3), pp.292-300. ⟨10.1097/QAI.0000000000001913⟩
Journal of Acquired Immune Deficiency Syndromes-JAIDS
Journal of Acquired Immune Deficiency Syndromes-JAIDS, 2019, 80 (3), pp.292-300. ⟨10.1097/QAI.0000000000001913⟩
Journal of Acquired Immune Deficiency Syndromes (1999)
Journal of Acquired Immune Deficiency Syndromes, Lippincott, Williams & Wilkins, 2019, 80 (3), pp.292-300. ⟨10.1097/qai.0000000000001913⟩
Gras, L, May, M, Ryder, L P, Trickey, A, Helleberg, M, Obel, N, Thiébaut, R, Guest, J, Gill, M J, Crane, H M, Lima, V D, Monforte, A D A, Sterling, T R, Miro, J, Moreno, S, Stephan, C, Smith, C, Tate, J P, Shepherd, L, Saag, M, Rieger, A, Gillor, D, Cavassini, M, Montero, M, Ingle, S, Reiss, P, Costagliola, D, Wit, F W N M, Sterne, J, de Wolf, F, Geskus, R 2019, ' Determinants of Restoration of CD4 and CD8 Cell Counts and their Ratio in HIV-1 Positive Individuals with Sustained Virological Suppression on Antiretroviral Therapy ', Journal of Acquired Immune Deficiency Syndromes, vol. 80, no. 3, pp. 292-300 . https://doi.org/10.1097/QAI.0000000000001913
Journal of acquired immune deficiency syndromes (1999), 80(3), 292-300. Lippincott Williams and Wilkins
Supplemental Digital Content is Available in the Text.
Background: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) with high CD4 cell counts. We investigated whether this makes restoration of CD4 and CD8 c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27619b29b391d2623e7858e2895d679e
http://ora.ox.ac.uk/objects/uuid:
Zobrazit plný text záznamu
9
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Autor: Brenda Homony, Claudine Duvivier, I Neves, Christine Katlama, Gordon Crofoot, Natalia Zakharova, Stefan Esser, Hedy Teppler, Xia Xu, Randi Y. Leavitt, Adriano Lazzarin, CR Mejia, M Mustafa, Olga Aleksandrovna Tsybakova, James H McMahon, Brian Conway, Juan Carlos Rondon, Faiza Ajana, TS Chow, M Oyanguren, EM Rojas, Jean-Michel Molina, A Avihingsanon, Carlos Perez, Koldo Aguirrebengoa, Karen T. Tashima, M Wolff, Yazdan Yazdanpanah, Eugenia Negredo, R Serrao, Richard James Moore, Carmen D. Zorrilla, Winai Ratanasuwan, C Echiverri, L Panther, Joel E. Gallant, Andri Rauch, HH Lin, Bernard Vandercam, Anthony John Scarsella, L Hercilla, A. Antinori, Pedro Cahn, Albrecht Stoehr, DE Sweet, Mariette E. Botes, Johannes R. Bogner, Hans Jaeger, Soumi Gupta, Olaf Degen, Nathan Clumeck, H. Hartl, PJ Ruane, Ckc Lee, Juergen K. Rockstroh, Richard Kaplan, N Roth, MF Lasso, Rassool, Gatell Jm, Markus Bickel, Nelson, M Moutschen, V Sotnikov, R Kaplan, Amanda Clarke, WH Sheng, Anchalee Avihingsanon, Doug Ward, L Vanderkerckhove, Daniel S Berger, Sasisopin Kiertiburanakul, Ghr Smith, Sandy L. Rawlins, Mohammed Rassool, A d'Arminio Monforte, Paul E. Sax, Margaret A. Johnson, F. Maggiolo, Fernando Maltez, Ramirez, Evgeny Voronin, Eyal Shahar, S Henn, Cheryl McDonald, A Ustianowski, MT Bloch, E Arathoon, Peter Sklar, LD Gonzalez, Enrique Ortega, Louis Sloan, Amneris E. Luque, Isabelle Poizot-Martin, M. H. Losso, Giuliano Rizzardini, Debbie Hagins, Lilly East, Andrea Gori, Matthias Cavassini, Princy Kumar, Isabel Cassetti, G. Di Perri, Benedetto Maurizio Celesia, Evelyn Rojas, S Ferret, Jerry L. Cade, KM Mullane, CB Hsiao, Dane Turner, Eugénio Teófilo, Bach-Yen Nguyen, Craig A. Dietz, Anthony Rodgers, Elena Orlova-Morozova, Z. Sthoeger, Jean-Guy Baril, Hila Elinav, I Khaertynova, JG Saraiva da Cunha, Carl J. Fichtenbaum, G Faetkanheuer, Peter Ruane, HC Tsai, R Iskandar Shah Raja Azwa, Lerato Mohapi, Firaya Nagimova, Keikawus Arastéh, J. Durant, JD Velez, Jacques Reynes, ST Lewis, Saag, Otto Sussmann, P. Cahn, D Changpradub, Mark Bloch, RM Novak, W Ratanasuwan, Kathleen Squires, Fiona Smaill, Larissa Wenning, Jose R. Arribas, Edwin DeJesus, Don Smith, JO Morales, A. Yakovlev, Sharon Walmsley, Carolina Eugenia Chahin, I Levy, Alexandra Calmy, David James Prelutsky, David M. Asmuth, Linos Vandekerckhove, J Troya, Antonio Antela, Alan Winston, Lizette Santiago, Juan Berenguer, Marcel Stoeckle, RA Castillo, Anita Rachlis
Publikováno v: Lancet HIV
Lancet HIV, Elsevier, 2017, 4 (11), pp.e486-e494. ⟨10.1016/S2352-3018(17)30128-5⟩
LANCET HIV
The Lancet HIV, Vol. 4, No 11 (2017) pp. e486-e494
Summary Background Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation. Methods In this
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b080de940b6244d90b7b170ca487b8b0
https://hal.archives-ouvertes.fr/hal-01745628
Zobrazit plný text záznamu
10
Short article
Autor: Tabernilla, Andrés, Grandal, Marta, Pernas, Berta, Castro-Iglesias, Angeles, Rodríguez-Osorio, Iria, Mena, Alvaro, Delgado, Manuel, Cid, Purificacion, Pedreira, Jose D, Poveda, Eva
OBJECTIVES: Direct-acting antiviral agents (DAAs) have provided an ultimate treatment duration of 12 weeks for most hepatitis C virus (HCV)-infected patients. The opportunity to reduce treatment duration to 6 or 8 weeks is being evaluated. Here, the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3848::27b5b69781753a2e3c5c7a01e33f28b4
https://doi.org/10.1097/meg.0000000000000882
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje